ASA: Pioglitazone After Stroke, TIA Helpful in Insulin Resistance

This article originally appeared here.
Share this content:
ASA: Pioglitazone After Stroke, TIA Helpful in Insulin Resistance
ASA: Pioglitazone After Stroke, TIA Helpful in Insulin Resistance

WEDNESDAY, Feb. 17, 2016 (HealthDay News) -- For patients with insulin resistance with recent stroke or transient ischemic attack (TIA), pioglitazone is associated with reduced risk of stroke or myocardial infarction, according to a study published online Feb. 17 in the New England Journal of Medicine. The research was published to coincide with the annual American Stroke Association's International Stroke Conference, held from Feb. 17 to 19 in Los Angeles.

Walter N. Kernan, M.D., from Yale University in New Haven, Conn., and colleagues randomized 3,876 patients with recent ischemic stroke or TIA to receive pioglitazone (target dose, 45 mg daily) or placebo. Eligible patients had insulin resistance, but did not have diabetes.

The researchers found that a primary outcome (fatal or nonfatal stroke or myocardial infarction) had occurred in 9.0 and in 11.8 percent of the pioglitazone and placebo groups, respectively, by 4.8 years (hazard ratio [HR], 0.76; 95 percent confidence interval [CI], 0.62 to 0.93). Diabetes developed in 3.8 and 7.7 percent of patients, respectively (HR, 0.48; 95 percent CI, 0.33 to 0.69). No significant between-group difference was seen in all-cause mortality (HR, 0.93; 95 percent CI, 0.73 to 1.17). Compared with placebo, pioglitazone was associated with a greater frequency of weight gain exceeding 4.5 kg, edema (both P < 0.001), and bone fracture requiring surgery or hospitalization (P = 0.003).

"We found that pioglitazone, a therapy directed at improving insulin sensitivity, can prevent cardiovascular events among patients who have insulin resistance along with cerebrovascular disease," the authors write.

Pioglitazone and placebo were provided by Takeda Pharmaceuticals.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths